-
1
المؤلفون: Claire Falandry, Fanny Pommeret, Laurence Gladieff, Fabien Tinquaut, Domenica Lorusso, Marie-Ange Mouret-Reynier, Véronique D'Hondt, Delphine Mollon-Grange, Anne Floquet, Sophie Abadie-Lacourtoisie, Pierre-Emmanuel Brachet, Laetitia Stefani, Frédérique Rousseau, Jean-Sébastien Frenel, Francesco Del Piano, Marja Komulainen, Thomas Warkus, Olivier Trédan, Eric Pujade-Lauraine, Gilles Freyer
المصدر: The Lancet Healthy Longevity. 3:e176-e185
مصطلحات موضوعية: Ovarian Neoplasms, Psychiatry and Mental health, Health (social science), Paclitaxel, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Carcinoma, Ovarian Epithelial, Geriatrics and Gerontology, Family Practice, Aged, Carboplatin
الوصف: Older patients with ovarian cancer represent a heterogeneous population. The French National Group of Investigators for the Study of Ovarian and Breast Cancer developed the geriatric vulnerability score (GVS) to identify geriatric parameters predictive of poor outcomes. A prospective validation of the GVS was needed.The EWOC-1 study (NCT02001272) was an international, open-label, phase 2, three-arm trial designed according to a two-step process. Patients aged 70 years or older with newly diagnosed stage III or IV ovarian cancer were identified and the GVS determined. Those with a GVS of 3 or greater were randomly assigned to the EWOC-1 trial, stratified by country and surgical outcome, to receive three different carboplatin with or without paclitaxel regimens; those not included in the EWOC-1 trial were followed up in the EWOC-1 registry. External validation of the GVS was a secondary endpoint of the trial. Three validation cohorts were identified: the total population (validation cohort 1 [V1], n=447), the registry-only population (validation cohort 2 [V2], n=327), and the carboplatin-paclitaxel-treated population (validation cohort 3 [V3], n=320).From Dec 11, 2013, to Nov 16, 2018, 447 patients were included in 48 academic centres in six countries; 120 in the EWOC-1 trial and 327 in the EWOC-1 registry. Median follow-up was 19·7 (95% CI 8·5-29·7) months for the total cohort; missing values were low (2%). According to the maximum likelihood analysis, the hazard ratio (HR) of death in V1 was 1·8 (95% CI 1·1-3·1, p=0·029) for those with a GVS of 1; 2·4 (1·4-4·0, p=0·0009) with a GVS of 2; 4·1 (2·5-7·0, p0·0001) for a GVS of 3; 5·5 (3·3-9·3, p0·0001) for a GVS of 4; and 9·1 (4·7-17·5, p0·0001) for a GVS of 5 compared with a score of 0. Whatever the validation cohort, GVS of 3 or more significantly segregated two groups with different overall survival: V1 (median 13·2 [95% CI: 10·8-18·7] vs 40·8 [32·0-45·6] months; HR 2·8 [95% CI 2·2-3·7]; p0·0001); V2 (11·9 [95% CI 8·8-18·1] vs 40·8 [32·0-45·6] months, HR 3·5 [2·5-4·9]; p0·0001); and V3 (18·1 [95% CI 15·8-31·8] vs 43·0 [40·6-49·7] months, HR 2·6 [1·9 to 3·7]; p0·0001).The GVS has high prognostic performance for overall survival in patients with advanced ovarian cancer, independently of geographic and historic effect (V1), as well as treatment patterns (V3), validated in an international population. Even though the GVS is time consuming it will allow the stratification of populations for clinical research and might permit the orientation of the geriatric intervention to specific domains.French National Cancer Institute.For the French translation of the abstract see Supplementary Materials section.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5d495706a6e073d16330079e57c32b8Test
https://doi.org/10.1016/s2666-7568Test(22)00002-2 -
2
المؤلفون: Gilles Freyer, Claire Falandry, Eric Pujade-Lauraine
المساهمون: CarMeN, laboratoire, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Groupe d'Investigateurs Nationaux pour l'Étude des Cancers de l'Ovaire et du sein [Paris] (GINECO), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), ARCAGY-GINECO, Université Paris Descartes - Paris 5 (UPD5)
المصدر: JAMA oncology
JAMA oncology, American Medical Association, 2021, 7 (11), pp.1727. ⟨10.1001/jamaoncol.2021.4131⟩مصطلحات موضوعية: Ovarian Neoplasms, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Optimal treatment, [SDV]Life Sciences [q-bio], Carcinoma, Ovarian Epithelial, medicine.disease, [SDV] Life Sciences [q-bio], Internal medicine, Humans, Medicine, Female, business, Ovarian cancer, ComputingMilieux_MISCELLANEOUS, Aged
الوصف: International audience; No abstract available
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf5471f511b32bddb063bd1bc235743aTest
https://www.hal.inserm.fr/inserm-03587199Test -
3
المؤلفون: Mojgan Devouassoux-Shisheboran, Blandine Courbiere, Marcos Ballester, G. Ferron, Claire Falandry, Sofiane Bendifallah, C. Sénéchal-Davin, Catherine Uzan, Chantal Touboul, Patricia Pautier, Naoual Bakrin, Fabrice Lecuru, François Planchamp, Marie-Aude Lefrère-Belda, L. Ouldamer, Sebastien Gouy, François Golfier, Nathalie Chabbert-Buffet, Eric Lambaudie, Laure Fournier, Christine Rousset-Jablonski, Fabrice Narducci, Cyrille Huchon, P. Alfonsi, Emile Daraï, F Guyon, Laurence Gladieff, C. Bourgin, Pierre-Adrien Bolze, Benoit You, V. Lavoué, A. Lemoine, Eric Leblanc, Fabrice Bonnet, Cherif Akladios, Nicolas Pouget, P. Collinet, T. de la Motte Rouge, I.L. Ray-Coquard, Alexandra Leary, Isabelle Thomassin-Naggara
المساهمون: Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de gynécologie et obstétrique [CHI Poissy-Saint Germain], CHI Poissy-Saint-Germain, CHU Strasbourg, Hôpital Saint-Luc-Saint-Joseph, service anesthésie-réanimation, Hôpital Saint-Luc-Saint-Joseph, Service d’Urologie [CHU Lyon Sud], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Groupe Hospitalier Diaconesses Croix Saint-Simon, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Jeanne de Flandres, CHRU de Lille, Institut méditerranéen de biodiversité et d'écologie marine et continentale (IMBE), Centre National de la Recherche Scientifique (CNRS)-Institut de recherche pour le développement [IRD] : UMR237-Aix Marseille Université (AMU)-Avignon Université (AU), Centre Eugène Marquis (CRLCC), Hospices Civils de Lyon (HCL), Institut Claudius Regaud, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Département de chirurgie gynécologique [Gustave Roussy], Institut Gustave Roussy (IGR), Institut Bergonié [Bordeaux], UNICANCER, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Oncologie gynécologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Département d’Hématologie Clinique [CHU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut Curie [Paris], Centre Léon Bérard [Lyon], Centre Hospitalier Intercommunal de Créteil (CHIC), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Avignon Université (AU)-Aix Marseille Université (AMU)-Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique (CNRS), Université de Lille-UNICANCER, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Jonchère, Laurent, Institut National de la Santé et de la Recherche Médicale (INSERM)-CRLCC Eugène Marquis (CRLCC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)
المصدر: Journal of Gynecology Obstetrics and Human Reproduction
Journal of Gynecology Obstetrics and Human Reproduction, Elsevier, 2019, 48 (6), pp.379-386. ⟨10.1016/j.jogoh.2019.03.018⟩
Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48 (6), pp.379-386. ⟨10.1016/j.jogoh.2019.03.018⟩مصطلحات موضوعية: endocrine system diseases, medicine.medical_treatment, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Fertility preservation, Stage (cooking), Peritoneal Neoplasms, Aged, 80 and over, Ovarian Neoplasms, 030219 obstetrics & reproductive medicine, Obstetrics and Gynecology, Fertility Preservation, female genital diseases and pregnancy complications, 3. Good health, Bevacizumab, medicine.anatomical_structure, Tubal cancer, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Hyperthermic intraperitoneal chemotherapy, Female, France, medicine.drug, Adult, medicine.medical_specialty, Paclitaxel, [SDV.CAN]Life Sciences [q-bio]/Cancer, Guidelines, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Ovarian cancer, medicine, Fallopian Tube Neoplasms, Humans, Chemotherapy, Aged, business.industry, Hyperthermia, Induced, medicine.disease, Primary peritoneal cancer, Surgery, Reproductive Medicine, chemistry, business, Fallopian tube
الوصف: International audience; Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc1cda25fef86511dec950d4e064a782Test
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02121103Test -
4
المؤلفون: Laurence Gladieff, Blandine Courbiere, Christine Rousset-Jablonski, Cyrille Huchon, Fabrice Lecuru, I.L. Ray-Coquard, Laure Fournier, Mojgan Devouassoux-Shisheboran, Chantal Touboul, Eric Lambaudie, Isabelle Thomassin-Naggara, Sebastien Gouy, Marie-Aude Lefrère-Belda, G. Ferron, Eric Leblanc, Benoit You, L. Ouldamer, V. Lavoué, C. Bourgin, Alexandra Leary, A. Lemoine, Francis Bonnet, C. Sénéchal-Davin, Emile Daraï, P. Collinet, Fabrice Narducci, P. Alfonsi, Naoual Bakrin, Marcos Ballester, Catherine Uzan, T. de la Motte Rouge, François Golfier, Nathalie Chabbert-Buffet, Pierre-Adrien Bolze, Cherif Akladios, Nicolas Pouget, Patricia Pautier, F Guyon, Claire Falandry, Sofiane Bendifallah, François Planchamp
المساهمون: Chemistry, Oncogenesis, Stress and Signaling (COSS), Institut National de la Santé et de la Recherche Médicale (INSERM)-CRLCC Eugène Marquis (CRLCC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut méditerranéen de biodiversité et d'écologie marine et continentale (IMBE), Avignon Université (AU)-Aix Marseille Université (AMU)-Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique (CNRS), Centre Eugène Marquis (CRLCC), Institut Claudius Regaud, Département de chirurgie gynécologique [Gustave Roussy], Institut Gustave Roussy (IGR), Institut Bergonié [Bordeaux], UNICANCER, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Oncologie gynécologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Institut Curie [Paris], Centre Léon Bérard [Lyon], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Carnot CALYM [Pierre-Benite], Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Lille-UNICANCER, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Carnot Lymphome (CALYM)
المصدر: Journal of Gynecology Obstetrics and Human Reproduction
Journal of Gynecology Obstetrics and Human Reproduction, Elsevier, 2019, 48 (6), pp.369-378. ⟨10.1016/j.jogoh.2019.03.017⟩
Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48 (6), pp.369-378. ⟨10.1016/j.jogoh.2019.03.017⟩مصطلحات موضوعية: Thorax, medicine.medical_specialty, medicine.medical_treatment, Ovary, [SDV.CAN]Life Sciences [q-bio]/Cancer, Guidelines, Perioperative Care, 03 medical and health sciences, 0302 clinical medicine, Ovarian cancer, Biomarkers, Tumor, Fallopian Tube Neoplasms, Humans, Minimally Invasive Surgical Procedures, Medicine, Chemotherapy, Neoplasms, Glandular and Epithelial, Neoplasm Metastasis, Peritoneal Neoplasms, Pelvis, Neoplasm Staging, Ovarian Neoplasms, 030219 obstetrics & reproductive medicine, business.industry, Obstetrics and Gynecology, medicine.disease, Primary peritoneal cancer, Magnetic Resonance Imaging, 3. Good health, Surgery, Omentectomy, medicine.anatomical_structure, Reproductive Medicine, Tubal cancer, 030220 oncology & carcinogenesis, Abdomen, Female, Laparoscopy, France, Tomography, X-Ray Computed, business, Fallopian tube
الوصف: International audience; An MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (grade A). In presumed early-stage ovarian or tubal cancers, the following procedures should be performed an omentectomy (at a minimum, infracolic), an appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C), and pelvic and para-aortic lymphadenectomies (grade B) for all histologic types, except the expansile mucinous subtypes, for which lymphadenectomies can be omitted (grade C). Minimally invasive surgery is recommended for early-stage ovarian cancer, when there is no risk of tumor rupture (grade B). For FIGO stages III or IV ovarian, tubal, and primary peritoneal cancers, a contrast-enhanced computed tomography (CT) scan of the thorax/abdomen/pelvis is recommended (grade B), as well as laparoscopic exploration to take multiple biopsies (grade A) and a carcinomatosis score (Fagotti score at a minimum) (grade C) to assess the possibility of complete surgery (i.e., leaving no macroscopic tumor residue). Complete surgery by a midline laparotomy is recommended for advanced ovarian, tubal, or primary peritoneal cancer (grade B). For advanced cancers, para-aortic and pelvic lymphadenectomies are recommended when metastatic adenopathy is clinically or radiologically suspected (grade B). When adenopathy is not suspected and when complete peritoneal surgery is performed as the initial surgery for advanced cancer, the lymphadenectomies can be omitted because they do not modify either the medical treatment or overall survival (grade B). Primary surgery (before other treatment) is recommended whenever it appears possible to leave no tumor residue (grade B).
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aefa87287108a3716355d76c295e1135Test
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02121102/documentTest -
5
المؤلفون: Nicolas Pouget, Francis Bonnet, Blandine Courbiere, Emile Daraï, François Planchamp, C. Sénéchal-Davin, Fabrice Lecuru, T. de la Motte Rouge, Pierre-Adrien Bolze, L. Ouldamer, Isabelle Thomassin-Naggara, I. Ray-Coquard, François Golfier, Nathalie Chabbert-Buffet, Laure Fournier, Laurence Gladieff, P. Collinet, Sebastien Gouy, Chantal Touboul, C. Bourgin, Benoit You, Catherine Uzan, Christine Rousset-Jablonski, Alexandra Leary, Cyrille Huchon, Patricia Pautier, Marie-Aude Lefrère-Belda, Naoual Bakrin, Cherif Akladios, Marcos Ballester, Vincent Lavoué, Sofiane Bendifallah, Claire Falandry, G. Ferron, Fabrice Narducci, P. Alfonsi, F Guyon, Eric Lambaudie, Eric Leblanc, A. Lemoine, Mojgan Devouassoux-Shisheboran
المساهمون: Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], CHU Strasbourg, Hôpital Saint-Joseph [Marseille], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Institut méditerranéen de biodiversité et d'écologie marine et continentale (IMBE), Avignon Université (AU)-Aix Marseille Université (AMU)-Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre Eugène Marquis (CRLCC), Institut Claudius Regaud, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de Radiologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Département de chirurgie gynécologique [Gustave Roussy], Institut Gustave Roussy (IGR), Institut Bergonié [Bordeaux], UNICANCER, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Oncologie gynécologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service d'anatomo-pathologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Léon Bérard [Lyon], Service de Pneumologie [CHI Créteil], CHI Créteil, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-CRLCC Eugène Marquis (CRLCC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
المصدر: European Journal of Obstetrics & Gynecology and Reproductive Biology
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2019, 236, pp.214-223. ⟨10.1016/j.ejogrb.2019.03.010⟩
European Journal of Obstetrics & Gynecology and Reproductive Biology, Elsevier, 2019, 236, pp.214-223. ⟨10.1016/j.ejogrb.2019.03.010⟩مصطلحات موضوعية: medicine.medical_specialty, Bevacizumab, medicine.medical_treatment, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Guidelines, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Ovarian cancer, medicine, Fallopian Tube Neoplasms, Humans, Minimally Invasive Surgical Procedures, Chemotherapy, 030212 general & internal medicine, Stage (cooking), Peritoneal Neoplasms, Ovarian Neoplasms, 030219 obstetrics & reproductive medicine, business.industry, Carcinoma, Obstetrics and Gynecology, medicine.disease, Primary peritoneal cancer, Carboplatin, female genital diseases and pregnancy complications, 3. Good health, medicine.anatomical_structure, Reproductive Medicine, chemistry, Tubal cancer, Abdomen, Female, Hyperthermic intraperitoneal chemotherapy, Surgery, France, Radiology, business, medicine.drug, Fallopian tube
الوصف: International audience; An MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (Grade A). In presumed early-stage ovarian or tubal cancers, the following procedures should be performed an omentectomy (at a minimum, infracolic), an appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C), and pelvic and para-aortic lymphadenectomies (Grade B) for all histologic types, except the expansile mucinous subtypes, for which lymphadenectomies can be omitted (grade C). Minimally invasive surgery is recommended for early-stage ovarian cancer, when there is no risk of tumor rupture (grade B). Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). For FIGO stage III or IV ovarian, tubal, and primary peritoneal cancers, a contrast-enhanced computed tomography (CT) scan of the thorax/abdomen/pelvis is recommended (Grade B), as well as laparoscopic exploration to take multiple biopsies (grade A) and a carcinomatosis score (Fagotti score at a minimum) (grade C) to assess the possibility of complete surgery (i.e., leaving no macroscopic tumor residue). Complete surgery by a midline laparotomy is recommended for advanced ovarian, tubal, or primary peritoneal cancers (grade B). For advanced cancers, para-aortic and pelvic lymphadenectomies are recommended when metastatic adenopathy is clinically or radiologically suspected (grade B). When adenopathy is not suspected and when complete peritoneal surgery is performed as the initial surgery for advanced cancer, the lymphadenectomies can be omitted because they do not modify either the medical treatment or overall survival (grade B). Primary surgery (before other treatment) is recommended whenever it appears possible to leave no tumor residue (grade B). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III disease, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::398e1efb51eb3b97af5fe69ff81127aaTest
https://univ-rennes.hal.science/hal-02088076Test -
6
المؤلفون: Vincent, Lavoue, Cyrille, Huchon, Cherif, Akladios, Pascal, Alfonsi, Naoual, Bakrin, Marcos, Ballester, Sofiane, Bendifallah, Pierre-Adrien, Bolze, Fabrice, Bonnet, Charlotte, Bourgin, Nathalie, Chabbert-Buffet, Pierre, Collinet, Blandine, Courbiere, Thibault, De la Motte Rouge, Mojgan, Devouassoux-Shisheboran, Claire, Falandry, Gwenal, Ferron, Laure, Fournier, Laurence, Gladieff, François, Golfier, Sébastien, Gouy, Frédérique, Guyon, Eric, Lambaudie, Alexandra, Leary, Fabrice, Lecuru, Marie-Aude, Lefrere-Belda, Eric, Leblanc, Adrien, Lemoine, Fabrice, Narducci, Lobna, Ouldamer, Patricia, Pautier, François, Planchamp, Nicolas, Pouget, Isabelle, Ray-Coquard, Christine, Rousset-Jablonski, Claire, Senechal-Davin, Cyril, Touboul, Isabelle, Thomassin-Naggara, Catherine, Uzan, Benoit, You, Emile, Daraï
المصدر: Bulletin du cancer. 106(4)
مصطلحات موضوعية: Ovarian Neoplasms, Antineoplastic Agents, Hyperthermia, Induced, Carcinoma, Ovarian Epithelial, Magnetic Resonance Imaging, Piperazines, Bevacizumab, Chemotherapy, Adjuvant, Fallopian Tube Neoplasms, Humans, Lymph Node Excision, Phthalazines, Female, France, Peritoneal Neoplasms, Societies, Medical, Ultrasonography
الوصف: Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A).
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::8c4281ba902b8c60fcdb6d1ba0a294b6Test
https://pubmed.ncbi.nlm.nih.gov/30850152Test -
7
المؤلفون: Nicolas Gane, Eric Pujade-Lauraine, Gilles Freyer, Franck Chauvin, Claire Falandry, Fabien Tinquaut
المساهمون: Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)
المصدر: Gynecologic Oncology
Gynecologic Oncology, Elsevier, 2016, 143 (1), pp.22-6. ⟨10.1016/j.ygyno.2016.03.018⟩مصطلحات موضوعية: Oncology, medicine.medical_specialty, Multivariate analysis, medicine.medical_treatment, Ovarian Neoplasms/*drug therapy/mortality, [SDV]Life Sciences [q-bio], Neutropenia, 03 medical and health sciences, chemistry.chemical_compound, Clinical Trials, Phase II as Topic, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, 80 and over, Humans, Clinical Trials, 030212 general & internal medicine, Hypoalbuminemia, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Prospective Studies, Stage (cooking), Prospective cohort study, Geriatric Assessment, Aged, Aged, 80 and over, Ovarian Neoplasms, Geriatrics, Chemotherapy, business.industry, Phase II as Topic, Obstetrics and Gynecology, General Medicine, medicine.disease, Prognosis, Carboplatin, 3. Good health, Surgery, Regimen, chemistry, 030220 oncology & carcinogenesis, Female, Ovarian cancer, business
الوصف: International audience; BACKGROUND: The GINECO led three multicentric prospective phase II studies, Elderly Woman Ovarian Trials 1 (EWOT1), EWOT2, and EWOT3, to evaluate the impact of geriatric covariates on the outcome of elderly patients treated with six courses of first-line chemotherapy for FIGO stage IIIIV ovarian cancer. This pooled analysis was designed to evaluate the validity of the geriatric vulnerability parameters identified in EWOT3 (Falandry et al., 2013). PATIENTS AND METHODS: From 1997 to 2011, 266 patients were recruited: 83 in EWOT1, 72 in EWOT2, and 111 in EWOT3, which evaluated respectively a 4-weekly carboplatin-cyclophosphamide regimen, a 3-weekly standard carboplatin-paclitaxel doublet and a carboplatin monotherapy. All patients were analyzed in this pooled analysis for treatment completion, toxicity, and overall survival. RESULTS: The global treatment completion rate was 73% and ranged from 68% in EWOT2 to 74% in EWOT3. Toxicities were generally manageable: neutropenia was more frequent in EWOT2 and thrombopenia in EWOT1 and EWOT3. In multivariate analysis, covariates associated with decreased survival were: being "depressed" according to the investigators' assessment, hypoalbuminemia \textless35g/L, and FIGO stage IV. In addition, a Hospital Anxiety and Depression Scale (HADS) score\textgreater14 and Instrumental Activities of Daily Living (IADL) score\textless25 confirmed a deleterious impact in the EWOT2+EWOT3 population subanalysis. CONCLUSIONS: Despite moderate heterogeneity among the studies, this pooled analysis confirmed the deleterious effects on overall survival of emotional disorders ("depressed", as assessed by investigators or the HADS score), and decreased functionality (IADL score), in addition to FIGO stage.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18a2479aa89f6eef8ee33694a4b83cecTest
https://hal.archives-ouvertes.fr/hal-01850366Test -
8
المؤلفون: M. Atlassi, Laetitia Stefani, J. Salvat, Fabien Tinquaut, F. Savinelli, Olivier Tredan, Emmanuel Sevin, Gilles Freyer, Aude Marie Savoye, Eric Pujade-Lauraine, Claire Falandry, Bettina Weber
المصدر: Annals of Oncology. 24:2808-2813
مصطلحات موضوعية: medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Population, Comorbidity, Hospital Anxiety and Depression Scale, Carboplatin, chemistry.chemical_compound, Internal medicine, Humans, Medicine, Prospective Studies, Adverse effect, education, Geriatric Assessment, Aged, Neoplasm Staging, Aged, 80 and over, Ovarian Neoplasms, Geriatrics, education.field_of_study, Performance status, business.industry, Hematology, Prognosis, medicine.disease, Survival Analysis, Chemotherapy regimen, Treatment Outcome, Oncology, chemistry, Physical therapy, Female, business
الوصف: Two previous GINECO elderly specific studies in advanced ovarian cancer (AOC) patients highlighted the prognostic value of geriatric covariates for overall survival (OS).This open-label prospective trial was designed to identify the impact of geriatric covariates on OS in AOC patients ≥70 years treated with first-line carboplatin.Geriatric covariates of the 111 patients included median age 79 years (≥80 years: 41%); performance status (PS) ≥2: 47%; ≥3 major comorbidities: 24%; ≥4 comedications: 68%; activities of daily living (ADL) score6: 55%; instrumental activities of daily living (IADL) score25: 69%; Hospital Anxiety and Depression Scale (HADS)14: 37%. The median OS was 17.4 months. Overall, 74% of patients completed the six planned chemotherapy cycles. Grade 3-4 haematological toxic effects were frequent (50%) but manageable. Grade 3-4 non-haematological toxicities included fatigue (15%), anorexia (12%), infections (9%) and thrombosis (2%). A survival score = exp(0.327*GVS) was developed, where the geriatric vulnerability score (GVS) is the sum of the following (each assigned a value of one): albuminaemia35 g/l; ADL score6; IADL score25; lymphopaenia1 G/l; and HADS14. With a cut-off ≥3, GVS discriminated two groups with significantly different OS, treatment completion, severe adverse events and unplanned hospital admissions rates.The GVS is a valuable tool for identifying vulnerable patients when treating an elderly AOC population.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::762b434fd810ef22bbd332babf896b5eTest
https://doi.org/10.1093/annonc/mdt360Test -
9
المؤلفون: Eric Pujade-Lauraine, Béatrice Horard, Jérôme Meunier, Jérôme Alexandre, Raymonde Maraval-Gaget, Michel Fabbro, Claire Falandry, Eric Legouffe, Eric Gilson, Gilles Freyer, Valérie Delecroix, Marie-Noëlle Certain, Amandine Bruyas, J. Cretin
المساهمون: Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Epigénétique et formation du zygote, Département génétique, interactions et évolution des génomes [LBBE] (GINSENG), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)
المصدر: Aging (Albany NY)
Aging
Aging, Impact Journals, 2015, 7 (12), pp.1066-76. ⟨10.18632/aging.100840⟩
Aging (Albany NY), 2015, 7 (12), pp.1066-76. ⟨10.18632/aging.100840⟩
Aging, 2015, 7 (12), pp.1066-76. ⟨10.18632/aging.100840⟩مصطلحات موضوعية: Oncology, Aging, Time Factors, [SDV]Life Sciences [q-bio], Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Pregnancy, 80 and over, 10. No inequality, prognostic factor, Aged, 80 and over, Ovarian Neoplasms, 0303 health sciences, telomere, Carboplatin/*therapeutic use, Antineoplastic Agents/*therapeutic use, 3. Good health, ovarian cancer, 030220 oncology & carcinogenesis, Female, Research Paper, Senescence, medicine.medical_specialty, geriatric, Antineoplastic Agents, elderly, 03 medical and health sciences, Telomere Homeostasis, Internal medicine, medicine, Humans, Prognostic biomarker, 030304 developmental biology, Telomere Homeostasis/*physiology, Aged, Neoplasm Staging, business.industry, Cancer, Cell Biology, medicine.disease, Telomere, chemistry, Ovarian Neoplasms/drug therapy/*metabolism, Ovarian cancer, business, Biomarkers
الوصف: International audience; PURPOSE: Age induces a progressive decline in functional reserve and impacts cancer treatments. Telomere attrition leads to tissue senescence. We tested the hypothesis that telomere length (TL) could predict patient vulnerability and outcome with cancer treatment. PATIENTS AND METHODS: An ancillary study in the Elderly Women GINECO Trial 3 was performed to evaluate the impact of geriatric covariates on survival in elderly advanced ovarian cancer patients receiving six cycles of carboplatin. TL was estimated from peripheral blood at inclusion using standard procedures. RESULTS: TL (in base pairs) was estimated for 109/111 patients (median 6.1 kb; range [4.5-8.3 kb]). With a cut-off of 5.77 kb, TL discriminated two patient groups, long telomere (LT) and short telomeres (ST), with significantly different treatment completion rates of 0.80 (95% CI [0.71-0.89]) and 0.59 (95% CI [0.41-0.76]), respectively (odds ratio [OR]=2.8, p=0.02). ST patients were at higher risk of serious adverse events (SAE, OR=2.7; p=0.02) and had more unplanned hospital admissions (OR=2.1; p=0.08). After adjustment on FIGO stage, TL shorter than 6 kb was a risk factor of premature death (HR=1.57; p=0.06). CONCLUSION: This exploratory study identifies TL as predictive factor of decreased treatment completion, SAE risk, unplanned hospital admissions and OS after adjustment on FIGO stage.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e2842be5465fd4b9295f07987d62c8Test
https://pubmed.ncbi.nlm.nih.gov/26638179Test -
10
المؤلفون: Claire Falandry, Gaelle Abgrall-Barbry, Pierre Saltel, Marilène Filbet, Rémi Largillier, Sophie Bourcelot, Gilles Freyer, Annick Le Rol, Virginie Adam, Olivier Gisserot, Franck Priou, Martine Derzelle, Jean-Louis Machavoine, Muriel Chomat-Neyraud, Wadih Rhondali
المساهمون: Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)
المصدر: Clinical Interventions in Aging
Clinical Interventions in Aging, Dove Medical Press, 2015, 10, pp.1155-62. ⟨10.2147/CIA.S71690⟩
Clinical Interventions in Aging, Vol Volume 10, Pp 1155-1162 (2015)مصطلحات موضوعية: Oncology, geriatric assessment, Psychiatric Status Rating Scales/*standards, [SDV]Life Sciences [q-bio], Medical Oncology, 0302 clinical medicine, 80 and over, 030212 general & internal medicine, Depression (differential diagnoses), Original Research, Clinical interview, Aged, 80 and over, Ovarian Neoplasms, General Medicine, Ovarian Neoplasms/mortality/*psychology, Medical Oncology/*methods, 3. Good health, Diagnostic and Statistical Manual of Mental Disorders, 030220 oncology & carcinogenesis, Montgomery–Åsberg Depression Rating Scale, depression, Female, medicine.medical_specialty, Depression/*psychology, Self Report/*standards, elderly, behavioral disciplines and activities, Sensitivity and Specificity, Interviews as Topic, 03 medical and health sciences, Rating scale, Geriatric Assessment/methods, Internal medicine, mental disorders, medicine, cancer, Humans, Psychiatry, Aged, Psychiatric Status Rating Scales, Advanced ovarian cancer, Performance status, business.industry, screening, RC952-954.6, Reproducibility of Results, Mood, Geriatrics, Clinical Interventions in Aging, Conventional PCI, Self Report, Geriatrics and Gerontology, business
الوصف: Wadih Rhondali,1 Gilles Freyer,2 Virginie Adam,3 Marilène Filbet,4 Martine Derzelle,5 Gaelle Abgrall-Barbry,6 Sophie Bourcelot,7 Jean-Louis Machavoine,8 Muriel Chomat-Neyraud,9 Olivier Gisserot,10 Rémi Largillier,11 Annick Le Rol,12 Frank Priou,13 Pierre Saltel,14 Claire Falandry15 1Clinique Mon Repos, Clinea, Marseille, France; 2Medical Oncology Unit, Centre Hospitalier Lyon Sud, Université Lyon 1, Pierre-Benite, France; 3Institut de Cancérologie de Lorraine Alexis Vautrin, Vandoeuvre-lès-Nancy, France; 4Palliative Unit, Centre Hospitalier Lyon Sud, Université Lyon 1, Pierre-Benite, France; 5Institut Jean Godinot, Reims, France; 6Tenon Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; 7Centre Léon Bérard, Lyon, France; 8Centre François Baclesse, Caen, France; 9Centre Hospitalier de la région d’Annecy, Pringy, France; 10Hôpital d’Instruction des Armées Sainte-Anne, Toulon, France; 11Centre Azuréen de Cancérologie, Mougins, France; 12Medical Oncology, Hôpital Perpétuel Secours, Levallois-Perret, France; 13Medical Oncology, Centre Hospitalier Départemental Les Oudairies, La Roche-sur-Yon, France; 14Supportive Care Department, Centre Léon Bérard, Lyon, France; 15Geriatrics and Oncology Unit, Centre Hospitalier Lyon Sud, Université Lyon 1, Pierre-Bénite, France Background: Depression, a major outcome in cancer patients, is often evaluated by physicians relying on their clinical impressions rather than patient self-report. Our aim was to assess agreement between patient self-reported depression, oncologist assessment (OA), and psychiatric clinical interview (PCI) in elderly patients with advanced ovarian cancer (AOC).Methods: This analysis was a secondary endpoint of the Elderly Women AOC Trial 3 (EWOT3), designed to assess the impact of geriatric covariates, notably depression, on survival in patients older than 70 years of age. Depression was assessed using the Geriatric Depression Scale-30 (GDS), the Hospital Anxiety Depression Scale, the distress thermometer, the mood thermometer, and OA. The interview guide for PCI was constructed from three validated scales: the GDS, the Hamilton Depression Rating Scale, and the Montgomery Asberg Depression Rating Scale (MADRS). The Diagnostic and Statistical Manual of Mental Disorders, fourth edition, revised (DSM) criteria for depression were used as a gold standard.Results: Out of 109 patients enrolled at 21 centers, 99 (91%) completed all the assessments. Patient characteristics were: mean age 78, performance status ≥2: 47 (47%). Thirty six patients (36%) were identified as depressed by the PCI versus 15 (15%) identified by DSM. We found moderate agreement for depression identification between DSM and GDS (κ=0.508) and PCI (κ=0.431) and high agreement with MADRS (κ=0.663). We found low or no agreement between DSM with the other assessment strategies, including OA (κ=-0.043). Identification according to OA (yes/no) resulted in a false-negative rate of 87%. As a screening tool, GDS had the best sensitivity and specificity (94% and 80%, respectively).Conclusion: The use of validated tools, such as GDS, and collaboration between psychologists and oncologists are warranted to better identify emotional disorders in elderly women with AOC. Keywords: depression, elderly, cancer, screening, geriatric assessment
وصف الملف: text/html
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de6878511240364b30da09459296183dTest
https://hal.archives-ouvertes.fr/hal-01850479Test